Abstract
B7-H3 (CD276), an immune checkpoint molecule, is overexpressed in various types of cancer and their tumor vasculature, demonstrating significant associations with adverse clinical outcomes. In addition to its well-known immune functions, B7-H3 exhibits dual co-stimulatory/co-inhibitory roles in normal physiology and the tumor microenvironment. The non-immune functions of B7-H3 in tumor cells and the tumor vasculature, including promoting tumor cell anti-apoptosis, proliferation, invasion, migration, drug resistance, radioresistance, as well as affecting cellular metabolism and angiogenesis, have increasingly gained attention from researchers. Particularly, the co-expression of B7-H3 in both tumor cells and tumor endothelial cells highlights the higher potential and clinical utility of therapeutic strategies targeting B7-H3. This review aims to summarize the recent advances in understanding the non-immune functions of B7-H3 in tumors and provide insights into therapeutic approaches targeting B7-H3, focusing on its co-expression in tumor cells and endothelial cells. The aim is to establish a theoretical foundation and practical reference for the development and optimization of B7-H3-targeted therapies.
1 Introduction
CD276, also known as B7 homolog 3 (B7-H3), is a type I transmembrane protein consisting of 316 amino acids. It is encoded by the gene located on chromosome 9 in mice and the human 15q24 region. The primary structure of B7-H3 includes an extracellular Ig-like domain, a transmembrane region, and a short cytoplasmic tail (). Based on the number of extracellular Ig-like domains, membrane-bound B7-H3 can be classified into two isoforms: 2IgB7-H3 and 4IgB7-H3. The former contains one IgV (variable) and one IgC (constant) domain, while the latter possesses tandem IgV and IgC domains due to exon duplication ().
B7-H3 is a cell surface tumor endothelial marker with up toĀ 30% amino acid homology to other members of the B7 family. ItĀ is also expressed in tumor-associated endothelial cells and is often associated with advanced tumor staging (). B7-H3 has been shown to differentiate pathological and physiological angiogenesis in both mice and humans (). The high expression of B7-H3 protein is observed in various human cancers such as lung, breast, colon, endometrial, renal, and ovarian cancer tumor vasculature, while it is not expressed in normal ovarian vasculature ().
Although initially characterized as a T-cell co-stimulatory protein, current research describes B7-H3 as a T-cell inhibitory molecule that promotes tumor invasion and proliferation. It mediates immune escape primarily by inhibiting T-cell infiltration and promoting CD8+ T-cell exhaustion, suggesting that B7-H3 may serve as an important immune target in cancer therapy (). However, B7-H3 also functions as an independent protein outside of the immune system, participating in non-immune responses in tumors. It plays a crucial role in tumor cell anti-apoptosis, proliferation, invasion, migration, drug resistance, radioresistance, metabolism, and angiogenesis (). The exact mechanisms through which B7-H3 promotes tumor development independently of the immune system are not fully understood. Nevertheless, extensive research suggests that B7-H3 may exert its effects upstream of signaling pathways, indicating that targeting these pathways could provide new approaches for cancer treatment (). The non-immune functions of B7H3 promoting tumor progression are summarized in FigureĀ 1.
FigureĀ 1
2 B7-H3 in the non-immune functions of tumors
2.1 Anti-apoptosis
Apoptosis is a genetically regulated, orderly process of cell death primarily responsible for eliminating aged or abnormal cells. Resistance to apoptosis has been widely recognized as a crucial hallmark of malignant tumors (). B7-H3 promotes tumor development by suppressing apoptosis in tumor cells (). In a multi-omic analysis and single-cell sequencing study, Zhou etĀ al. found a significant increase in B7-H3 levels during the cellular senescence process in tumor cells, suggesting a critical role of B7-H3 in preventing tumor cell senescence (). On the other hand, the role of B7-H3 in tumor growth has also garnered attention. Early studies on breast cancer cells demonstrated that silencing B7-H3 expression in the MCF-7 cell line led to an upregulation of vascular endothelial growth factor (VEGF) at both mRNA and protein levels, indicating that B7-H3 may inhibit tumor growth by suppressing VEGF expression (). However, subsequent research revealed that the expression of B7-H3 actually facilitates tumor growth in other breast cancer cell lines, suggesting a complex and potentially contradictory role of B7-H3 in the pathogenesis of breast cancer (). These findings indicate that B7-H3 may play a multifaceted role in the development of tumors, with specific effects likely dependent on the tumor type, underlying mechanisms, and biological context. Nonetheless, the majority of current research supports the view that B7-H3 promotes tumor growth through its anti-apoptotic effects. The summary of signaling pathways mediating the anti-apoptotic effects of B7-H3 is presented in TableĀ 1.
TableĀ 1
| Function | Cancer Type | Mechanism | References |
|---|---|---|---|
| Anti-apoptosis | Colorectal Cancer | Upregulates the Jak2-Stat3 signaling pathway to enhance the expression of downstream anti-apoptotic proteins Bcl-2 and Bcl-xl, thereby strengthening tumor cell resistance against apoptosis | () |
| Colorectal Cancer | Suppresses cellular senescence in colorectal cancer cells through the AKT/TM4SF1/SIRT1 pathway | () | |
| Gastric Cancer | Inhibits tumor cell apoptosis by regulating the PI3K/AKT signaling pathway mediated by fibronectin | () | |
| Cervical Intraepithelial Neoplasia and Cervical Cancer | Induces tumor cell apoptosis by modulating the E7/Rb pathway, affecting cell cycle and apoptosis | () | |
| Proliferation, Invasion, Migration | Breast Cancer | Regulates MEK to induce tumor stem cell proliferation | () |
| Head and Neck Squamous Cell Carcinoma | Activates AP-1 to promote cancer stem cell invasion and metastasis | () | |
| Ovarian Cancer | Affects tumor cell invasion, migration, and proliferation through the Jak2/Stat3 pathway | () | |
| Gastric Cancer | Silencing B7-H3 downregulates CXCR4 related to metastasis and inhibits phosphorylation of AKT, ERK, and Jak2/Stat3, suppressing tumor cell migration and invasion | () | |
| Glioblastoma | Enhances tumor cell proliferation and invasion through the activation of Jak2/Stat3/Slug signaling pathway. Induces EMT process by downregulating E-cadherin and upregulating MMP-2/9 expression, leading to increased invasion of glioblastoma cells | () | |
| Pancreatic Ductal Adenocarcinoma | BRD4/B7-H3/TLR4 axis promotes tumor cell proliferation, invasion, and metastasis | () | |
| Liver Cancer | Targets epithelial-mesenchymal transition (EMT) through the Jak2/Stat3/Slug signaling pathway while promoting the expression of MMP-2 and MMP-9 to enhance tumor metastasis and invasion | () | |
| Non-Small Cell Lung Cancer | Upregulates SIRT1 expression through the PI3K/AKT pathway, activating EMT and inducing migration | () | |
| Melanoma | Knockdown of B7-H3 reduces MMP-2 mRNA levels and proMMP-2 protein expression, as well as decreases phosphorylation of Stat3 and secretion of IL-8, leading to decreased metastatic capability | () | |
| Breast Cancer | Accelerates lung metastasis by activating the Raf/MEK/ERK signaling pathway | () | |
| Clear Cell Renal Cell Carcinoma | Promotes tumor cell invasion and metastasis in a fibronectin-dependent manner, accompanied by upregulation of phosphorylated proteins in the PI3K/AKT and p38/ERK MAPK signaling pathways | () | |
| Drug Resistance | Breast Cancer | Partially induces paclitaxel resistance by interfering with the Jak2/Stat3 pathway | () |
| Pancreatic Cancer | Induces gemcitabine resistance through downregulation of survivin expression | () | |
| Melanoma | Mediates dacarbazine and cisplatin resistance via DUSP10-mediated p38 MAPK inactivation | () | |
| Colorectal Cancer | Upregulates expression of X-ray repair cross-complementing protein 1 (XRCC1) through the PI3K-AKT pathway, promoting oxaliplatin resistance | () | |
| Colorectal Cancer | Reduces G2/M phase arrest in a CDC25A-dependent manner, enhancing resistance to oxaliplatin or 5-fluorouracil | () | |
| Ovarian Cancer | Induces activation of the PI3K/AKT signaling pathway, leading to treatment resistance | () | |
| Metabolism | Esophageal Squamous Cell Carcinoma | Induces phosphorylation of PKM2 through the Stat3 signaling pathway, promoting glucose metabolism | () |
| Breast Cancer | Regulates glucose metabolism by inhibiting Nrf2 and its target genes, increasing protein levels of HIF1α, LDHA, and PDK1 | () | |
| Colorectal Cancer | Regulates glucose metabolism by inhibiting Nrf2 and its target genes, increasing protein levels of HIF1α, LDHA, and PDK1 | () | |
| Oral Squamous Cell Carcinoma | Enhances glycolysis by upregulating Glut1 and PFKFB3 through the PI3K/AKT/mTOR/HIF-1α pathway | () | |
| Colorectal Cancer | Regulates glucose metabolism by controlling the expression of HK2 | () | |
| Neuroblastoma | Increases glucose uptake and lactate production by regulating the Stat3/c-Met pathway and increasing PFKFB3 expression | () | |
| Angiogenesis | Neuroblastoma | Induces angiogenesis through MMP-2 and MMP-9 | () |
| Colorectal Cancer | Upregulates VEGFA expression and promotes angiogenesis by activating the NF-ĪŗB pathway | () | |
| Colorectal Cancer | Promotes tumor angiogenesis and metastasis through activation of the AKT1/mTOR/VEGFA signaling pathway | () | |
| Breast Cancer | Inhibits tumor growth by suppressing VEGF expression | () | |
| Clear Cell Renal Cell Carcinoma | Promotes angiogenesis through the Tie-2 pathway | () | |
| Angiogenic Mimicry | NSCLC | Promotes VM formation in NSCLC cells through the PI3K/AKT signaling pathway | () |
| Hepatocellular Carcinoma | Promotes VM formation by activating the PI3K/AKT/MMPs pathway and upregulating the expression of MMP2, MMP14, VE-cadherin, and vimentin during EMT process | () |
Signaling Pathways Mediating the Diverse Functions of B7-H3.
B7-H3, B7 homolog 3; Jak2, Janus kinase 2; TM4SF1, transmembraneā4 L6 family member 1; SIRT1, sirtuin 1;Nrf2 and its target genes, increasing protein levels of HIF1α, hypoxiaāinducible factorā1α; LDHA, lactate dehydrogenase A; PDK1, phosphoinositide-dependent protein kinase-1; PFKFB3, 6-Phosphofructo 2-kinase/fructose 2, 6-bisphosphatase 3;VM, vasculogenic mimicry.
2.2 Proliferation, invasion, migration
Recent studies have revealed the significant role of B7-H3 in promoting cancer cell proliferation, migration, and invasion (, , , ). In various cancers, including oral cancer, hepatocellular carcinoma, colorectal cancer, lung adenocarcinoma, hematologic malignancies, and gynecologic tumors, B7-H3 has been found to promote cancer cell proliferation by regulating different signaling pathways (). B7-H3 can also enhance cancer cell migration by modulating the expression of E-cadherin, increasing their migratory capacity (). Additionally, B7-H3 can augment cancer cell invasion into surrounding tissues by regulating the activity of matrix metalloproteinases (MMPs) (). These findings provide us with new insights and suggest that targeting B7-H3 and its associated signaling pathways could be an effective strategy for the treatment of these cancers. The summary of signaling pathways mediating the proliferation, invasion, and migration effects of B7-H3 is presented in TableĀ 1.
2.3 Drug resistance
Drug resistance is a reflection of tumor evolution and is a major cause of cancer recurrence and patient mortality (). Studies have shown that overexpression of B7-H3 often leads to drug resistance in cancer cells. Different mechanisms of resistance exist in different tumor cells. For example, the high expression of the B7-H3 immune checkpoint protein in neuroblastoma is involved in carcinogenic signaling, tumor cell plasticity, and theĀ development of drug resistance (). However, inhibiting the expression of B7-H3 or blocking its associated signaling pathways can reverse this resistance. One approach is to use a combination of paclitaxel and MEK inhibitors to block the B7-H3 signal, which has been demonstrated to effectively reverse chemotherapy resistance (). Another approach is to use the specific inhibitor LY294002 to block the PI3K signaling pathway, which can also effectively inhibit this resistance (). Another study found that bromodomain and extra-terminal domain inhibitors could be used to reduce the levels of B7-H3 protein and mRNA in pancreatic cancer cells, providing a new therapeutic strategy to overcome immune and chemotherapy resistance in pancreatic cancer (). In related studies on traditional Chinese medicine, researchers found that artemisinin-mediated inhibition of B7-H3 may help enhance neuroblastoma cell sensitivity to doxorubicin (). Additionally, Astragaloside IV enhanced the chemosensitivity to cisplatin by inhibiting B7-H3, suggesting that a combination therapy using Astragaloside IV and a B7-H3 inhibitor may be a potential treatment method for lung cancer patients (). The summary of signaling pathways mediating the drug resistance effects of B7-H3 is presented in TableĀ 1.
2.4 Radiation resistance
Radiation therapy is a common treatment modality for solidĀ tumors; however, radiation resistance is a major factor contributing to treatment failure in cancer (). A study by Ma etĀ al. reported an interesting phenomenon: after X-ray irradiation, the expression of B7-H3 was upregulated in colorectal cancer cells, and this upregulation depended on the upregulation of KIF15 via the NF-ĪŗB signaling pathway. Further research revealed that B7-H3/KIF15, through activation of the ERK1/2 signaling pathway, promoted radiation resistance in colorectal cancer (). Additionally, Zhou etĀ al. found that B7-H3 increased the radiation resistance of gastric cancer cells by regulating baseline levels of cellular autophagy. In cells with high B7-H3 expression, increasing the baseline level of cellular autophagy using rapamycin enhanced their sensitivity to radiation (). These studies all point to the important role of B7-H3 in regulating tumor cell resistance to radiation therapy. Therefore, finding effective ways to inhibit or modulate the expression and function of B7-H3 may provide new strategies to improve the effectiveness of radiation therapy.
2.5 Metabolism
The Warburg effect is one of the characteristic features of tumor cell metabolism, where cancer cells tend to produce energy through glycolysis even in the presence of abundant oxygen, which is significantly different from the metabolic mechanism of normal cells (). Research by Lim etĀ al. found that B7-H3 plays an important role in the metabolic reprogramming of cancer cells. In cells expressing B7-H3, glucose uptake and lactate production are increased (). On the other hand, there is an interaction between the glycolytic enzyme ENO1 and B7-H3. Downregulation of B7-H3 in cervical cancer HeLa cells leads to decreased levels of ATP, lactate, c-Myc, and lactate dehydrogenase A (). Furthermore, overexpression of B7-H3 effectively increases glucose consumption and lactate production rate, while knockout of B7-H3 has the opposite effect. Liu etĀ al. demonstrated that using the anti-B7-H3 antibody 8H9 can shift cellular metabolism from glycolysis to oxidative phosphorylation, and they suggested that anti-B7-H3 blockade may alter tumor glucose metabolism through reactive oxygen species-mediated pathways by measuring cellular ROS levels in A549 cells treated with the anti-B7-H3 antibody using fluorescence probes (). In addition to changes in glucose metabolism, cancer cells often possess altered fatty acid metabolism properties. In glioma cells, genetic risk features associated with fatty acid catabolism are significantly correlated with the immune checkpoint molecule B7-H3 (). These research findings further emphasize the important role of B7-H3 in the metabolic regulation of cancer cells and may provide new therapeutic strategies for targeting this process. The summary of signaling pathways mediating the metabolism effects of B7-H3 is presented in TableĀ 1.
3 The role of B7-H3 in tumor vasculature and clinical treatment
3.1 The role of B7-H3 in tumor vasculature
In cancer development, angiogenesis plays a crucial role by providing oxygen and nutrients to tumors while allowing their spread to other parts of the body. Thus, inhibiting or reducing the blood supply in the tumor microenvironment to restrict tumor angiogenesis has become a key strategy against various solid tumors (). B7-H3 is a highly expressed protein in many types of cancer, including lung, breast, colorectal, endometrial, renal, ovarian, hepatocellular carcinoma, and melanoma. However, this protein is not expressed in normal vascular tissues (, ). Furthermore, in hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, and melanoma, the expression rate of B7-H3 in the tumor vasculature reaches 86% to 98% (). In ovarian cancer, although the expression rate of B7-H3 is only 44%, it is undetectable in normal ovarian vascular tissues ().
Under normal physiological conditions, the process of angiogenesis is strictly regulated by factors that promote and inhibit angiogenesis to maintain a stable internal environment and prevent uncontrolled blood vessel growth. However, B7-H3 protein can disrupt this balance by enhancing the activity of several pro-angiogenic factors, favoring tumor development (). It mainly activates multiple signaling pathways, such as MMP-2, MMP-9, NF-ĪŗB, AKT1/mTOR/VEGFA, and Tie-2, thus promoting tumor angiogenesis and further facilitating tumor growth and spread (ā). By inhibiting key molecules in these signaling pathways, we can effectively inhibit angiogenesis. For example, in neuroblastoma, overexpression of miR-29 can activate the JAK/STAT1 signaling pathway, weakening the regulatory effect of MYC-B7-H3 and inhibiting tumor angiogenesis (). Additionally, Wang etĀ al. found that recombinant VEGFA can eliminate the inhibitory effect of shB7-H3 on human umbilical vein endothelial cell angiogenesis in conditioned medium from colorectal cancer cells. Furthermore, siRNA against VEGFA or neutralizing antibodies against VEGFA can reverse the effects of B7-H3 in overexpressed colorectal cancer cell-conditioned medium on human umbilical vein endothelial cell angiogenesis (). These studies further elucidate the potential role of B7-H3 in tumor angiogenesis and may serve as a crucial target for future anti-angiogenic therapies.
Moreover, B7-H3 also plays an important role in vasculogenic mimicry (VM). VM is an alternative microcirculation pattern independent of angiogenesis, where cancer cells form microvascular-like channels to provide nutrients and oxygen to tumors (). Recent studies have found that B7-H3 expressed in tumors promotes VM formation in non-small cell lung cancer cells through the PI3K/AKT signaling pathway without affecting normal angiogenesis, providing a new strategy for future anticancer therapies (). The summary of signaling pathways mediating B7-H3-induced tumor angiogenesis is presented in TableĀ 1.
3.2 Clinical treatment
In numerous types of tumors, the widespread overexpression of B7-H3 on cancer cells and tumor-associated blood vessels makes it a potential ideal dual-target for therapy. CD276-ADC, utilizing pyrrolobenzodiazepine as a linker, demonstrates significant cytotoxicity against cancer cells while also exhibiting remarkable destructive effects on the tumor vascular system. This therapy shows great potential in eradicating large existing tumors and metastatic lesions, with the possibility of significantly improving long-term overall survival rates for patients (). To target the overexpression of B7-H3 in tumor cells and tumor vasculature, along with its limited expression in normal tissue vasculature, researchers have employed an innovative strategy by conjugating the Fab fragment of anti-CD276 antibody with the photosensitizer IRDye700 to form a novel CD276-targeted agent. The findings show that combining photodynamic therapy using this agent with inhibition strategies targeting the PD-L1/PD-1 axis can induce strong local and systemic anti-tumor responses, effectively eliminating primary and metastatic tumors (). Chen etĀ al. reported the development of pH-responsive drug release using B7H3-targeted doxorubicin-conjugated gold nano-cages (B7H3/Dox@GNCs), which represents a selective, precise, and synergistic chemotherapy-photothermal therapy for NSCLC, capable of simultaneously destroying B7H3-positive tumor cells, tumor-associated vasculature, and cancer-associated fibroblasts (). The expression of B7-H3 in the tumor vasculature can also be utilized to significantly improve the diagnostic accuracy of breast cancer, which is undoubtedly an important discovery ().
Furthermore, as a promising immunotherapy target, B7-H3 has been applied in combination treatment strategies. When used as a key element in T cell co-stimulation and anti-angiogenesis therapy for hepatocellular carcinoma, the effect of B7-H3 is significantly superior to using these treatments alone. Injecting plasmids expressing B7-H3 into subcutaneous tumors in mice resulted in complete eradication of these tumors within 24 hours, which was not achieved when using angiostatin or B7-H3 treatment alone (). This process revealed the ability of angiostatin gene transfer to inhibit tumor angiogenesis and enhance NK cell infiltration, as well as the critical role of B7-H3 in activating CD8+ tumor infiltration, increasing circulating IFN-c levels, and even completely regressing distant tumor nodules (). However, although B7-H3 plays an important role in the aforementioned combination treatment strategies, its primary role in the broader field of immunotherapy is still as an immune checkpoint inhibitor. For example, in the treatment of triple-negative breast cancer, Cheng etĀ al. found that blocking B7-H3 with anti-B7-H3 antibodies improved the abnormal state of the tumor vascular system, thereby enhancing the effects of chemotherapy and PD-1 treatment (). These research findings further emphasize that B7-H3 can serve as an important therapeutic target in anticancer treatment strategies, whether used alone or in combination with other treatment modalities. More clinical trials targeting B7-H3 for cancer treatment are listed in TableĀ 2.
TableĀ 2
| Intervention type | Intervention | Trial number | Phase | Cancer type |
|---|---|---|---|---|
| ADCC | MGA271 | NCT01918930 | I | Melanoma |
| NCT02982941 | I | Neuroblastoma Rhabdomyosarcoma Osteosarcoma | ||
| NCT01391143 | I | Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer | ||
| NCT0298294 | I | Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor | ||
| NCT02923180 | II | Prostate Cancer | ||
| DS-5573a | NCT02192567 | I | Advanced Solid Malignant Tumors | |
| ADC | MGC018 | NCT03729596 | I/II | Advanced Solid Malignant Tumors |
| I-DXd | NCT05280470 | II | Extensive-stage Small-cell Lung Cancer | |
| NCT06330064 | II | Recurrent or Metastatic Solid Tumors | ||
| NCT06203210 | III | Small Cell Lung Cancer | ||
| NCT06362252 | Ib/II | Extensive Stage-small Cell Lung Cancer | ||
| HS-20093 | NCT06112704 | II | Advanced Solid Tumors | |
| NCT06332170 | I | Advanced Solid Tumors | ||
| NCT05830123 | II | Osteosarcoma Sarcoma | ||
| NCT05276609 | I | Advanced Solid Tumors | ||
| NCT06001255 | II | Metastasis Castration Resistant Prostate Cancer(mCRPC) | ||
| NCT06007729 | II | Head and Neck Squamous Cell Carcinoma | ||
| BAT8009 | NCT05405621 | I | Locally Advanced/Metastatic Solid Tumours | |
| DS-7300a | NCT04145622 | I/II | Advanced Solid Tumor Malignant Solid Tumor | |
| B7-H3 X CD3 BiAb | MGD009 | NCT02628535 | I | 13 Types of Tumors |
| CAR-T | B7-H3-CAR T cells | NCT04897321 | I | 15 Types of Tumors |
| NCT05835687 | I | 7 Types of Central Nervous System Tumors | ||
| NCT04185038 | I | 10 Types of Central Nervous System Tumors | ||
| NCT04670068 | I | Epithelial Ovarian Cancer | ||
| NCT05474378 | I | Brain and Nervous System | ||
| NCT05366179 | I | Glioblastoma Multiforme | ||
| NCT05190185 | I | Malignant Melanoma, Lung Cancer, or Colorectal Cancer | ||
| NCT04385173 | I | Recurrent Glioblastoma Refractory Glioblastoma | ||
| NCT04077866 | I/II | Recurrent Glioblastoma Refractory Glioblastoma | ||
| NCT05241392 | I | Glioblastoma | ||
| NCT04864821 | Early Phase 1 | Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer | ||
| NCT05143151 | I/II | Advanced Pancreatic Carcinoma | ||
| NCT05562024 | I | B7-H3-positive Relapsed/Refractory Neuroblastoma | ||
| NCT06221553 | Early Phase 1 | DIPG Brain Tumor Diffuse Intrinsic Pontine Glioma | ||
| second generation 4ā1BBζ B7H3-EGFRt-DHFR | NCT04483778 | I | 16 Types of Pediatric Solid Tumors | |
| SC- CAR 4BRAIN | NCT05768880 | I | Malignant Central Nervous System Neoplasm | |
| B7-H3 UCAR-T cell | NCT05752877 | Advanced Glioma Complication of Chimeric Antigen Receptor (CAR-T) Cell Therap | ||
| KT095 CAR-T cell | NCT05515185 | Early Phase 1 | Advanced Solid Tumor | |
| B7-H3 and 11 other engineered CAR-T | NCT04842812 | I | Liver CancerLung CancerBreast CancerColo-rectal CancerBrain TumorSolid Tumor, AdultPD1CTLA4 | |
| 4SCAR-276 | NCT04432649 | I/II | Solid Tumor | |
| fhB7H3.CAR-Ts | NCT05211557 | I/II | Ovarian Cancer | |
| EGFR/B7H3 CAR-T | NCT05341492 | Early Phase 1 | EGFR/B7H3-positive Advanced Lung/Breast Cancer | |
| B7-H3 and 10 other CAR-T | NCT03198052 | I | Lung Cancer | |
| iC9-CAR.B7-H3 T cells | NCT06305299 | I | Ovary Neoplasm Ovarian Cancer Epithelial Ovarian Cancer | |
| NCT06347068 | I | Breast Cancer Relapse Resistant Cancer | ||
| 4SCAR-T cells | NCT04637503 | I/II | Neuroblastoma | |
| CAR-γΓ T | B7-H3-CAR -γΓ T cells | NCT06018363 | Brain Gliomas | |
| CAR-gd T | B7-H3-CAR -gd T cells | NCT05731219 | Relapsed/Refractory Acute Myeloid Leukemia | |
| NCT05722171 | Relapsed/Refractory Acute Myeloid Leukemia | |||
| Radioimmunotherapy | 124I-omburtamab | NCT01502917 | I | Brain Cancer Brain Stem Glioma |
| 177Lu-DTPA-omburtamab | NCT04167618 | I/II | Medulloblastoma, Childhood | |
| NCT04315246 | I/II | Leptomeningeal Metastasis Solid Tumor, Adult | ||
| 131I-omburtamab | NCT00089245 | I | Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma | |
| NCT00582608 | Not Applicable | CNS Cancer, Neuroblastoma, Sarcoma | ||
| NCT01099644 | I | Peritoneal Cancer | ||
| NCT03275402 | II/III | Neuroblastoma, CNS Metastases, Leptomeningeal Metastases | ||
| NCT04022213 | II | Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma | ||
| NCT05064306 | Central Nervous, System/Leptomeningeal, Neoplasms | |||
| NCT04743661 | II | Recurrent Medulloblastoma Recurrent Ependymoma | ||
| NCT05063357 | I | DIPG | ||
| Anti-B7-H3 ADCC with Anti-PD-1 Ab | MGA271/pembrolizumab/MGA 012 | NCT02475213 | I | Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urethelial Carcinoma |
| Enoblituzumab MGA012 MGD013 | NCT04129320 | II/III | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | |
| Anti-B7-H3 ADCC with Anti-PD-1 Ab or PD-1 X LAG-3 BiAb | MGA271/MGA012/MGD013 | NCT04634825 | II | Head and neck cancer |
| Anti-B7-H3 ADC with Anti-PD-1 Ab | MGC018/MGA012 | NCT03729596 | I/II | 6 advanced solid tumors |
| B7-H3 CD3 BiAb with Anti-PD-1 Ab | MGD009/MGA012 | NCT03406949 | I | Advanced Solid Tumors |
| Anti-B7-H3 ADC with CD19 X CD3 BiAb | MGC018/MGD019 | NCT05293496 | I | 7 advanced solid tumors |
| Anti-B7-H3 ADCC with NK cell enhancing | MGA271/FT516 and IL2 | NCT04630769 | I | Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer |
| Anti-B7-H3 ADCC with Anti-CTLA-4 Ab | enoblituzumab plus ipilimumab | NCT02381314 | I | Melanoma, Non Small Cell Lung Cancer |
Clinical Trials Targeting B7-H3.
4 Conclusion
Compared to other immune checkpoints, the uniqueness of B7-H3 lies in its ability to regulate both innate and adaptive immune responses. Furthermore, it promotes tumor development by stimulating various non-immune-related functions, making it anĀ important prognostic marker for adverse outcomes. B7-H3Ā influences the life processes of tumor cells, including apoptosis, proliferation, invasion, migration, drug resistance, resistanceĀ toĀ radiotherapy, metabolic processes, and abnormal angiogenesis, through the regulation of various signaling pathways. Therefore, inhibiting B7-H3 expression or blocking related signaling pathways may be an effective approach to prevent tumor progression.
Considering the high expression of B7-H3 in tumor cells and tumor vasculature, along with its low expression in normal vasculature, it becomes an ideal dual-target in cancer therapy. By considering B7-H3 as a bridge between tumor cells and the tumor vascular system, we can achieve dual therapeutic effects by targeting B7-H3. However, since the role and signaling pathways of B7-H3 may vary among different tumors and even within the vascular systems of different tumors, gaining a deeper understanding of the specific functions of B7-H3 in particular tumors will help us design more targeted treatment plans for patients, thus effectively controlling tumor development. This could be an important direction for future research in cancer therapy.
Statements
Author contributions
SW: Writing ā original draft, Writing ā review & editing. CH: Visualization, Writing ā review & editing. KH: Visualization, Writing ā review & editing. XJ: Conceptualization, Writing ā review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
The authors thank all members involved in this work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
KontosFMichelakosTKurokawaTSadagopanASchwabJHFerroneCRet al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. (2021) 27:1227ā35. doi:Ā 10.1158/1078-0432.CCR-20-2584
2
KanchanRKDossDKhanPNasserMWMahapatraS. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. Biochim Biophys Acta (BBA) Rev Cancer. (2022) 1877:188783. doi:Ā 10.1016/j.bbcan.2022.188783
3
Flem-KarlsenKFodstadĆTanMNunes-XavierCE. B7-H3 in cancer ā beyond immune regulation. Trends Cancer. (2018) 4:401ā4. doi:Ā 10.1016/j.trecan.2018.03.010
4
SeamanSStevensJYangMYLogsdonDGraff-CherryCSt. CroixB. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. (2007) 11:539ā54. doi:Ā 10.1016/j.ccr.2007.04.017
5
SeamanSZhuZSahaSZhangXMYangMYHiltonMBet al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. (2017) 31:501ā515.e8. doi:Ā 10.1016/j.ccell.2017.03.005
6
MortezaeeK. B7-H3 immunoregulatory roles in cancer. BioMed Pharmacother. (2023) 163:114890. doi:Ā 10.1016/j.biopha.2023.114890
7
FengYXieKYinYLiBPiCXuXet al. A novel anti-B7-H3 Ć Anti-CD3 bispecific antibody with potent antitumor activity. Life (Basel). (2022) 12:157. doi:Ā 10.3390/life12020157
8
SunMXieJZhangDChenCLinSChenYet al. B7-H3 inhibits apoptosis of gastric cancer cell by interacting with Fibronectin. J Cancer. (2021) 12:7518ā26. doi:Ā 10.7150/jca.59263
9
ZhouXOuyangSLiJHuangXAiXZengYet al. The novel non-immunological role and underlying mechanisms of B7-H3 in tumorigenesis. J Cell Physiol. (2019) 234:21785ā95. doi:Ā 10.1002/jcp.28936
10
ZhangQTangYHuGYuanZZhangSSunYet al. Comprehensive pan-cancer analysis identifies cellular senescence as a new therapeutic target for cancer: multi-omics analysis and single-cell sequencing validation. Am J Cancer Res. (2022) 12:4103ā19.
11
SunJGuoYDLiXNZhangYQGuLWuPPet al. B7-H3 expression in breast cancer and upregulation of VEGF through gene silence. Onco Targets Ther. (2014) 7:1979ā86. doi:Ā 10.2147/OTT
12
Montoyo-PujolYGGarcĆa-EscolanoMPonceJJDelgado-GarcĆaSMartĆnTABallesterHet al. Variable intrinsic expression of immunoregulatory biomarkers in breast cancer cell lines, mammospheres, and co-cultures. Int J Mol Sci. (2023) 24:4478. doi:Ā 10.3390/ijms24054478
13
ZhangTJiangBZouSTLiuFHuaD. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. (2015) 21:1804ā13. doi:Ā 10.3748/wjg.v21.i6.1804
14
WangRSunLXiaSWuHMaYZhanSet al. B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway. Cell Death Dis. (2021) 12:453. doi:Ā 10.1038/s41419-021-03736-2
15
HanSShiXLiuLZongLZhangJChenQet al. Roles of B7-H3 in cervical cancer and its prognostic value. J Cancer. (2018) 9:2612ā24. doi:Ā 10.7150/jca.24959
16
LiuZZhangWPhillipsJBAroraRMcClellanSLiJet al. Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene. (2019) 38:88ā102. doi:Ā 10.1038/s41388-018-0407-9
17
WangCLiYJiaLKimJKLiJDengPet al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. (2021) 28:1597ā1613.e7. doi:Ā 10.1016/j.stem.2021.04.011
18
ZhangJLiuLHanSLiYQianQZhangQet al. B7-H3 is related to tumor progression in ovarian cancer. Oncol Rep. (2017) 38:2426ā34. doi:Ā 10.3892/or.2017.5858
19
LiYYangXWuYZhaoKYeZZhuJet al. B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget. (2017) 8:71725ā35. doi:Ā 10.18632/oncotarget.v8i42
20
ZhongCTaoBChenYGuoZYangXPengLet al. B7-H3 regulates glioma growth and cell invasion through a JAK2/STAT3/slug-dependent signaling pathway. Onco Targets Ther. (2020) 13:2215ā24. doi:Ā 10.2147/OTT
21
ZhaoJMengZXieCYangCLiuZWuSet al. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. (2019) 108:84ā91. doi:Ā 10.1016/j.biocel.2019.01.011
22
KangFBWangLJiaHCLiDLiHJZhangYGet al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. (2015) 15:45. doi:Ā 10.1186/s12935-015-0195-z
23
LiaoHDingMZhouNYangYChenL. B7āH3 promotes the epithelialāmesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway. Mol Med Rep. (2022) 25:79. doi:Ā 10.3892/mmr
24
TekleCNygrenMKChenYWDybsjordINeslandJMMaelandsmoGMet al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer. (2012) 130:2282ā90. doi:Ā 10.1002/ijc.26238
25
WangSZhangXNingHDongSWangGSunR. B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis. Breast Cancer Res Treat. (2022) 193:405ā16. doi:Ā 10.1007/s10549-022-06520-8
26
XieJSunMZhangDChenCLinSZhangG. Fibronectin enhances tumor metastasis through B7-H3 in clear cell renal cell carcinoma. FEBS Open Bio. (2021) 11:2977ā87. doi:Ā 10.1002/2211-5463.13280
27
LiuHTekleCChenYWKristianAZhaoYZhouMet al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther. (2011) 10:960ā71. doi:Ā 10.1158/1535-7163.MCT-11-0072
28
ZhaoXZhangGBGanWJXiongFLiZZhaoHet al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. (2013) 5:805ā12. doi:Ā 10.3892/ol.2013.1118
29
Flem-KarlsenKTekleCĆyjordTFlĆørenesVAMƦlandsmoGMFodstadĆet al. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Sci Rep. (2019) 9:5839. doi:Ā 10.1038/s41598-019-42303-w
30
ZhangPChenZNingKJinJHanX. Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells. Biochem Biophys Res Commun. (2017) 490:1132ā8. doi:Ā 10.1016/j.bbrc.2017.07.001
31
MaYWangRLuHLiXZhangGFuFet al. B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A. J Cancer. (2020) 11:2158ā70. doi:Ā 10.7150/jca.37255
32
ZhouLZhaoY. B7-H3 induces ovarian cancer drugs resistance through an PI3K/AKT/BCL-2 signaling pathway. Cancer Manag Res. (2019) 11:10205ā14. doi:Ā 10.2147/CMAR
33
YueGTangJZhangLNiuHLiHLuoS. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma. J Gastrointest Oncol. (2021) 12:38ā51. doi:Ā 10.21037/jgo
34
LimSLiuHMadeira da SilvaLAroraRLiuZPhillipsJBet al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1α. Cancer Res. (2016) 76:2231ā42. doi:Ā 10.1158/0008-5472.CAN-15-1538
35
LiZLiuJQueLTangX. The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway. J Cancer. (2019) 10:5770ā84. doi:Ā 10.7150/jca.29838
36
ShiTMaYCaoLZhanSXuYFuFet al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. (2019) 10:308. doi:Ā 10.1038/s41419-019-1549-6
37
ZhuXShiYWangJ. B7-H3 regulates glucose metabolism in neuroblastom via stat3/c-met pathway. Appl Biochem Biotechnol. (2023) 196:1386ā98. doi:Ā 10.1007/s12010-023-04606-7
38
PurvisIJAvilalaJGudaMRVenkataramanSVibhakarRTsungAJet al. Role of MYC-miR-29-B7-H3 in medulloblastoma growth and angiogenesis. J Clin Med. (2019) 8:1158. doi:Ā 10.3390/jcm8081158
39
WangRMaYZhanSZhangGCaoLZhangXet al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-ĪŗB pathway to induce VEGFA expression. Cell Death Dis. (2020) 11:55. doi:Ā 10.1038/s41419-020-2252-3
40
WuRZhangYXuXYouQYuCWangWet al. Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway. Cell Signal. (2023) 109:110737. doi:Ā 10.1016/j.cellsig.2023.110737
41
ZhangXJiJZhangGFangCJiangFMaSet al. Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma. Onco Targets Ther. (2017) 0:5417ā24. doi:Ā 10.2147/OTT
42
FanXHuangJHuBZhouJChenL. Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer. J Cancer Res Clin Oncol. (2023) 149:8729ā41. doi:Ā 10.1007/s00432-023-04790-3
43
ChengRWangBCaiXRChenZSDuQZhouLYet al. CD276 promotes vasculogenic mimicry formation in hepatocellular carcinoma via the PI3K/AKT/MMPs pathway. Onco Targets Ther. (2020) 13:11485ā98. doi:Ā 10.2147/OTT.S271891
44
HuXXuMHuYLiNZhouL. B7-H3, negatively regulated by miR-128, promotes colorectal cancer cell proliferation and migration. Cell Biochem Biophys. (2021) 79:397ā405. doi:Ā 10.1007/s12013-021-00975-0
45
LiYZhangJHanSQianQChenQLiuLet al. B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis. Oncol Rep. (2017) 38:1043ā50. doi:Ā 10.3892/or.2017.5730
46
TangXYLuoZLXiongYLYangJShiAPZhengKFet al. The proliferative role of immune checkpoints in tumors: double regulation. Cancers (Basel). (2022) 14:5374. doi:Ā 10.3390/cancers14215374
47
ShiYXuYXuZWangHZhangJWuYet al. TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression. Cancer Lett. (2022) 532:215583. doi:Ā 10.1016/j.canlet.2022.215583
48
PulidoRNunes-XavierCE. Hopes on immunotherapy targeting B7-H3 in neuroblastoma. Transl Oncol. (2023) 27:101580. doi:Ā 10.1016/j.tranon.2022.101580
49
JiangBLiuFLiuZZhangTHuaD. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. Tumour Biol. (2016) 37:9465ā72. doi:Ā 10.1007/s13277-015-4740-0
50
TanWQChenGYeMJiaB. Artemether regulates chemosensitivity to doxorubicin via regulation of B7-H3 in human neuroblastoma cells. Med Sci Monit. (2017) 23:4252ā9. doi:Ā 10.12659/MSM.902068
51
WangSMouJCuiLWangXZhangZ. Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3. BioMed Pharmacother. (2018) 102:1037ā44. doi:Ā 10.1016/j.biopha.2018.03.127
52
WangXCYueXZhangRXLiuTYPanZZYangMJet al. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating nonhomologous end joining repair. Clin Cancer Res. (2019) 25:4567ā79. doi:Ā 10.1158/1078-0432.CCR-18-3735
53
DeBerardinisRJLumJJHatzivassiliouGThompsonCB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. (2008) 7:11ā20. doi:Ā 10.1016/j.cmet.2007.10.002
54
ZuoJWangBLongMGaoZZhangZWangHet al. The type 1 transmembrane glycoprotein B7-H3 interacts with the glycolytic enzyme ENO1 to promote Malignancy and glycolysis in HeLa cells. FEBS Lett. (2018) 592:2476ā88. doi:Ā 10.1002/1873-3468.13164
55
LiuJYangSCaoBZhouGZhangFWangYet al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. (2021) 14:21. doi:Ā 10.1186/s13045-020-01024-8
56
QiYChenDLuQYaoYJiC. Bioinformatic profiling identifies a fatty acid metabolism-related gene risk signature for Malignancy, prognosis, and immune phenotype of glioma. Dis Markers. (2019) 2019:3917040. doi:Ā 10.1155/2019/3917040
57
Al-OstootFHSalahSKhameesHAKhanumSA. Tumor angiogenesis: Current challenges and therapeutic opportunities. Cancer Treat Res Commun. (2021) 28:100422. doi:Ā 10.1016/j.ctarc.2021.100422
58
MichelakosTKontosFBarakatOMaggsLSchwabJHFerroneCRet al. B7-H3 targeted antibody-based immunotherapy of Malignant diseases. Expert Opin Biol Ther. (2021) 21:587ā602. doi:Ā 10.1080/14712598.2021.1862791
59
de la CruzONHLópez-GonzĆ”lezJSGarcĆa-VĆ”zquezRSalinas-VeraYMMuƱiz-LinoMAAguilar-CazaresDet al. Regulation networks driving vasculogenic mimicry in solid tumors. Front Oncol. (2020) 9:1419. doi:Ā 10.3389/fonc.2019.01419
60
BaoRWangYLaiJZhuHZhaoYLiSet al. Enhancing anti-PD-1/PD-L1 immune checkpoint inhibitory cancer therapy by CD276-targeted photodynamic ablation of tumor cells and tumor vasculature. Mol Pharm. (2019) 16:339ā48. doi:Ā 10.1021/acs.molpharmaceut.8b00997
61
ChenBZhengKFangSHuangKChuCZhuangJet al. B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC. J Nanobiotechnol. (2023) 21:378. doi:Ā 10.1186/s12951-023-02078-9
62
KastenBBArendRCKatreAAKimHFanJFerroneSet al. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. (2017) 47:23ā30. doi:Ā 10.1016/j.nucmedbio.2017.01.003
63
MaLLuoLQiaoHDongXPanSJiangHet al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol. (2007) 46:98ā106. doi:Ā 10.1016/j.jhep.2006.07.031
64
ChengNBeiYSongYZhangWXuLZhangWet al. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Biochem Pharmacol. (2021) 183:114298. doi:Ā 10.1016/j.bcp.2020.114298
Summary
Keywords
B7-H3, non-immune functions, tumor cells, tumor vasculature, cancer therapy
Citation
Wu S, Hu C, Hui K and Jiang X (2024) Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature. Front. Oncol. 14:1408051. doi: 10.3389/fonc.2024.1408051
Received
27 March 2024
Accepted
04 June 2024
Published
17 June 2024
Volume
14 - 2024
Edited by
Nitesh Kumar, National Institute of Pharmaceutical Education and Research, India
Reviewed by
Gautam Kumar, Sharda University, India
Sri Pragnya Cheruku, Manipal University, India
Updates
Copyright
Ā© 2024 Wu, Hu, Hui and Jiang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaodong Jiang, jxdpaper@163.com; Kaiyuan Hui, kyhui1987@163.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.